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Introduction
Locoregional treatment as well as systemic therapy for 
primary breast cancer have both changed. NSABP B-04 (1) 
showed that axillary lymph node dissection (ALND) did 
not significantly improve 10-year overall survival (OS). 
Furthermore, OS did not differ significantly between 
patients who did not receive ALND and those undergoing 
ALND after receiving a diagnosis of axillary lymph node 
recurrence (AR). NSABP B-32 (2), ACOSOG Z0010 (3) 
and other studies have provided evidence supporting the 
use of sentinel lymph node (SN) biopsy in patients with 
clinically node negative breast cancer. Omitting ALND 
in node negative breast cancer resulted in significantly 
better quality of life due to avoidance of lymphedema. 
Furthermore, the Z0011 trial showed that ALND could be 
omitted even in selected patients with positive SN status. 
The 10-year postoperative locoregional recurrence rate of 
primary breast cancer is reportedly approximately 10% (4). 
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The frequency of ipsilateral AR or ipsilateral supraclavicular 
lymph node recurrence (SR) was reported to be 3% or 
less. However, omitting ALND of SN positive patients 
might increase the rate of AR (5,6). On the other hand, SR 
worsens distant disease free survival (DFS) and increases the 
risk of death (7-9). 
We do not presently have sufficient evidence based 
established therapeutic strategies for isolated locoregional 
lymph node recurrence. For AR, if possible, surgical 
excision should be carried out followed by radiotherapy, if 
the patients have not previously undergone radiotherapy. As 
for SR, combining systemic therapy and radiotherapy, rather 
than performing surgery, might be recommended (10). 
These strategies tend to be individually tailored, and 
consistent decision-making policies are needed. In this 
review series, we focused especially on isolated AR and 
SR in patients receiving systemic therapies combined with 
surgery. 
Treatment of AR
AR rates were 0.8–1.3% (11,12) in patients who underwent 
surgical intervention for primary breast cancer. We 
reviewed 4 studies (12-15) taking surgical treatment into 
consideration. The first author’s name, year of publication, 
study period, and primary breast cancer information 
(pathological stage of primary disease, surgical therapy 
and adjuvant radiotherapy) are listed Table 1. The numbers 
of patients were 44 to 220. Lee et al. reported isolated 
locoregional recurrence. The patient ages ranged from 
48 to 61 years. The pathological primary disease stage 
was mentioned in two studies (12,15), and stages I and II 
accounted for at least 75% of tumors. The types of surgery 
performed for primary breast cancer are also listed. From 
66% to 100% of patients underwent ALND. Radiotherapy 
was administered to 15% to 73% of patients. 
Types of treatment and clinical outcomes of patients 
with AR are listed in Table 2. DFS was 20 to 36 months. 
Surgery and either radiotherapy or systemic treatments 
were selected. From 69% to 77% of patients underwent 
surgery. The 5-year OS rates ranged from 39% to 46%. 
Lee et al. reported isolated locoregional recurrence, and 
their results are thus not included in this series. de Boer 
et al. reported the distant DFS rate to be 35%. Negative 
and positive prognostic factors are also listed. de Boer et al. 
concluded that “positive lymph node metastases of primary 
cancer”, “tumor size of primary cancer” and “eradication 
of AR (R0)” were associated with good outcomes. R0 
status was confirmed in 47% of patients. The R0 group 
had significantly better outcomes than those with residual 
tumor (median OS was 4.8 vs. 1.9 years, P=0.01). Lee et al. 
and Konkin et al. noted long DFS to be associated with 
good outcomes. Konkin et al. mentioned that regimens 
combining surgery with other therapies contributed to 
good outcomes. Newman et al. reported initial therapies for 
AR: 45.5% of patients underwent surgery; 45.5% received 
chemotherapy; 4.5% radiotherapy; and 4.5% hormone 
therapy. Subtypes of AR tumors were provided in the report 
by Lee et al. (hormone receptor positive/HER2 negative 
34%, HER2 positive/hormone receptor positive or negative 
35%, triple negative 14%, unknown 17%).
 We do not have data from a prospective randomized 
control study of surgical therapy for AR. While there are 
selection biases for AR surgery, these data show that surgery 
when combined with radiotherapy and/or systemic therapy 
has clinical benefits. 
Treatment of SR
As to primary treatment of advanced breast cancer, 
aggressive resection of supraclavicular lymph node 
metastases did not improve patient outcomes (16). In terms 
of SR, there are no randomized control studies examining 
whether outcomes of patients with SR and AR improve with 
versus without surgical treatment. Isolated SR is a more 
extensive disease than isolated AR. Isolated SR was observed 
in 0.8–2.6% of patients who underwent curative surgery 
for primary breast cancer. However, patients with isolated 
SR have better outcomes than those with SR and distant 
metastases (5,17-19). van der Sangen et al. (5) reported 
outcomes of isolated SR, without distant metastases, 
in 42 patients diagnosed with breast cancer during the 
period from 1984 to 1994. Median time to diagnosis of 
SR was 2.5 years. In total, radiotherapy was administered 
to 25 patients. Radiotherapy only was administered to 4 
patients, while 5 received both radiotherapy and surgery, 
and 16 patients underwent radiotherapy with surgery and/
or hormone therapy. Seventeen patients in total were not 
given radiotherapy. Eleven patients received hormone 
therapy only, 4 chemotherapy only, and one surgery 
only, while one patient was untreated. Thirty-five (38%) 
patients achieved complete remission, but recurrences were 
observed in 12 (34% of those with complete remission). 
The 5-year actuarial OS rate was 38% (95% CI, 23–53%). 
The 5-year DFS rate was 22% (95% CI, 8–35%). The 
distant DFS was better for patients given radiotherapy than 
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for those not receiving radiotherapy (P=0.06). However, 
only a few retrospective studies with small sample sizes have 
examined this issue (19,20). Reddy et al. (17) reviewed long-
term outcomes of patients with SR after initial treatment 
with doxorubicin-based chemotherapy and mastectomy. 
Although the patients with locoregional recurrence 
including SR and lymphatic invasion or vascular invasion of 
primary tumors have poorer distant DFS (hazard ratio, 1.96, 
P=0.004), OS of patients with isolated SR did not different 
significantly from that of those with more extensive 
locoregional disease. 
There are a few reports describing the utility of surgical 
treatment for isolated SR (18,21). However, there have 
been no randomized controlled trials comparing surgical 
to non-surgical treatment for SR. Chen et al. identified 
63 patients with SR without distant metastases in a single 
institute. Median follow-up was 58.3 months. Thirty-
five (56%) of the 63 patients died within the observation 
period. Median DFS was 25 months. The only significant 
risk factor was age at diagnosis of SR (>40). The 5-year OS 
rate was significantly better for patients in the operation 
group (42.4% vs. 16.3%). The patients with isolated SR 
had 5-year OS nearly equivalent to that of patients who had 
isolated local recurrence (33.6% vs. 34.9%), but better than 
Table 1 Stage details and adjuvant therapy for primary tumor
Author, year 
(reference)




de Boer, 2001, (12) 1984–1994 59 61 [39–99] NS NS NS Mastectomy + ALND 41%; BCS 
+ ALND 56% 
54%
Newman, 2000, (13) 1982–1992 44 48 [25–74]* 18% 55% 25% Mastectomy 5%; Mastectomy 
+ ALND 66%; BCS 4%; BCS + 
ALND 25%
NS
Lee, 2016, (14) 2000–2010 104 <40 28%; 40–50 
44%; >50 28%*
43% 39% 17% Mastectomy 41%; BCS 59%** 73%
Konkin, 2006, (15) 1989–2003 220 59.5 (mean)* NS NS NS ALND 81%; no ALND 19%*** 15%
*, primary diagnosis; **, axillary surgery not described; ***, breast surgery not described. NS, not stated; BCS, breast conserving surgery; 
ALND, axillary lymph node dissection; DFS, disease free survival.










Negative or positive prognostic factors
de Boer, 
2001, (12)
31 [4–128] Surgery and/or RT and/or systemic 
69%; RT and/or systemic 30%
NS 39% Good: negative for lymph node metastases 




20 [3–117] Surgery in combination 75%; 





36 [4–132] NS CT 30%; HT 35%; 
RT 35%
77%** Negative: age <35, high grade of primary 
tumor, early recurrence (<24 months), triple 
negative subtype of primary tumor
Konkin, 
2006, (15)
26 [2–143] Surgery 73%* CT 24%; HT 68%; 
RT 65%
46% positive factors for OS: long DFS (>2.5 years), 
no RT with primary surgery, no symptoms,  
combination of surgery with RT and/or 
systemic therapy
*, combination therapy not described; **, all data pertaining to isolated locoregional recurrence. NS, not stated; DFS, disease free survival; 
RT, radiotherapy; CT, chemotherapy; HT, hormone therapy; R0, microscopic complete resection. 
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that of patients with distant metastases (33.6% vs. 9.1%). 
Of course, there might be a selection bias, not only in terms 
of systemic therapy or radiotherapy, but also surgery for 
SR which is effective for neck control and improving the 
survival rate. Pederson et al. investigated early breast cancer 
patients with isolated ipsilateral SR. They extracted 305 
patients diagnosed with SR, but free of distant metastases, 
from the database of the Danish Breast Cancer Cooperative 
Group. As to the primary tumor, 74% of patients had 
axillary lymph node metastases. Forty-six percent of patients 
were hormone receptor positive. DFS was 27 months (range, 
2–114 months). The tumor sizes of SR cases were ≤10 mm 
in 30%, 11–20 mm in 34%, and >20 mm in 19%. Nearly 
half of the patients had developed SR by 2 years after the 
primary surgery. The types of therapy for SR were surgery 
and radiotherapy in 10% (excisional surgery: 19%, curative 
radiotherapy: 33%), endocrine and chemotherapy in 11% 
(endocrine therapy: 40%, chemotherapy: 45%), local and 
systemic therapy in 26% (systemic therapy only: 49%, 
no systemic therapy: 25%). The 5-year progression free 
survival (PFS) rate was 15%, median PFS was 18 months, 
5-year OS was 24%, and median OS was 29 months. As to 
prognostic factors, complete remission was related to better 
outcomes (P<0.0001), and systemic therapy prolonged PFS. 
Most notably, a combination of systemic and loco-regional 
treatment reduced progression. All of these factors were 
identified by univariate analysis. On multivariate analysis, 
combination therapy was an independent factor associated 
with improved PFS, as compared to local therapy only, 
and negative lymph node status and low tumor grade at 
the diagnosis of the primary disease were also independent 
factors related to PFS. Salvage treatment and tumor grade 
were significantly associated with OS. 
In summary, we have reviewed a small number of 
retrospective and non-randomized studies. The outcomes 
of patients with isolated SR are better than those of patients 
with distant metastases. The effectiveness of surgical 
resection for improving the OS of patients with isolated SR 
remains controversial, while regimens combining systemic 
treatments and radiotherapy with surgery might contribute 
to good neck control, better PFS, and longer OS. The 
treatment decisions must be made by cancer board, and the 
risks of surgical treatment must be taken into consideration. 
The results of further investigations are thus needed. 
Future perspectives
There is a report describing recurrence risk according 
to receptor phenotypes (22). Lowery et al. investigated 
the relationship between locoregional recurrence and 
the primary cancer subtype. Estrogen receptor and/or 
progesterone receptor positive patients had a lower risk of 
locoregional recurrence than those with triple negative and 
HER2/neu-over-expressing tumors after breast conserving 
surgery (RR 0.38; 95% CI: 0.23–0.61, RR 0.34; 95% CI: 
0.26–0.45, respectively) Mastectomy patients had results 
very similar to those of patients receiving breast conserving 
surgery. HER2/neu-over-expressing tumors carried a higher 
risk of locoregional recurrence than triple negative tumors 
after breast conserving surgery (RR 1.44; 95% CI: 1.06–
1.95). However, after mastectomy, these two groups showed 
no difference in locoregional recurrence rates. HER2/
neu-over-expressing and triple negative tumors tended to 
have a high risk of locoregional recurrence, regardless of 
whether breast conserving surgery or mastectomy had been 
performed, suggesting that local and systemic treatments 
should be tailored to each subtype. Michel et al. (23) also 
reported risk prediction based on locoregional recurrence 
by using the CPS + EG score which predicts distant 
metastases. The score is calculated based on clinical stage, 
post-treatment pathological stage, estrogen receptor status, 
and tumor grade. They divided patients into 6 prognostic 
groups with 5-year locoregional recurrence free survival and 
5-year distant metastasis free survival, which ranged from 
100–41% (P=0.02), and 96–35% (P<0.0001, respectively). 
If risks of locoregional recurrence can be reliably assessed, 
tailored adjuvant treatment for primary breast cancer might 
this type of recurrence and thereby improve the outcomes 
of patients with isolated AR, SR, and other forms of 
locoregional recurrence.
Surgical treatment for locoregional recurrence aims 
not only to cure but also diagnose metastatic lymph 
nodes. Thangarajah et al. (24) reported discordance  of 
receptor status between primary and metastatic sites of SR. 
Discordance rates between primary tumor and metastatic 
sites in terms of estrogen, progesterone, and Her2 receptor 
status were 20.0%, 36.8%, and 29.4%, respectively. When 
treating SR, combination therapy achieves better local 
control, longer DFS, improved rates of being distant 
metastases free and better OS, such that optimal selection 
of systemic therapy is crucial. Surgical treatment of SR is 
also contributes to improved outcomes. 
In terms of systemic therapy, we now have a wider 
range of novel drugs for breast cancer. Molecularly-
targeted therapies such as anti- HER2 agents, including 
trastuzumab, pertuzumab and T-DM1 (25,26), immune 
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checkpoint inhibitors (ICI) such as humanized monoclonal 
anti–PD-L1 antibody (Atezolizumab) (27), and PARP 
inhibitors have shown efficacy for BRCA (BReast CAncer 
gene)-positive HER2 negative metastatic breast cancers (28) 
and are thereby contributing to better outcomes not only 
for metastatic breast cancer patients but also those receiving 
adjuvant therapy for primary breast cancer. Regimens 
combining local treatment and systemic therapy appear to 
be highly effective, even potentially curative, and further 
investigations are thus needed. 
Conclusions
We reviewed clinical outcomes of combining surgery with 
other treatments for AR, and examined the role of surgery 
for isolated SR. Although further investigation employing 
a prospective randomized clinical study design is needed, 
appropriate surgical therapy with minimum morbidity 
combined with radiotherapy and/or the newer, effective 
systemic agents improves the clinical outcomes of breast 
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